⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3051327 | 0.92 | — | — | |
| SCHEMBL4149012 | 0.90 | MAPK1 (0.44) | — | |
| SCHEMBL3050112 | 0.90 | MAPK1 (0.44) | — | |
| SCHEMBL15194211 | 0.90 | MAPK1 (0.44) | — | |
| SCHEMBL17275134 | 0.90 | MAPK1 (0.44) | — | |
| SCHEMBL4230147 | 0.90 | MAPK1 (0.44) | — | |
| SCHEMBL4155026 | 0.90 | MAPK1 (0.44) | — | |
| SCHEMBL17634017 | 0.90 | MAPK1 (0.44) | — | |
| SCHEMBL20919713 | 0.90 | MAPK1 (0.44) | — | |
| SCHEMBL246942 | 0.82 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 653 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239787-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2024-07-18 | — | — | US | disclosed |
| US-12037336-B2 | Compounds with activity as inhibitors of the epithelial sodium channel (ENaC) | Enterprise Therapeutics Limited (GB) | 2024-07-16 | — | — | US | disclosed |
| US-12037344-B2 | NLRP3 modulators | INNATE TUMOR IMMUNITY, INC (US) | 2024-07-16 | — | — | US | disclosed |
| US-20240226343-A1 | NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY, INC. | 2024-07-11 | — | — | US | disclosed |
| WO-2024140401-A1 | HETEROCYCLIC COMPOUND ACTING AS KINASE INHIBITOR, AND COMPOSITION COMPRISING SAME | 捷思英达控股有限公司 | 2024-07-04 | — | — | WO | disclosed |
| EP-4392409-A1 | PYRAZINE COMPOUNDS AS IRREVERSIBLE INHIBITORS OF FLT3 | Biomea Fusion, Inc. (US) | 2024-07-03 | — | — | EP | disclosed |
| US-20240208910-A1 | ISOQUINOLINE COMPOUNDS AND THEIR USE IN TREATING AhR IMBALANCE | Dermavant Sciences GmbH (CH) | 2024-06-27 | — | — | US | disclosed |
| EP-3377473-B1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | RQX PHARMACEUTICALS INC (US) | 2024-06-19 | — | — | EP | disclosed |
| EP-4385988-A1 | SUBSTITUTED TRIAZOLE DERIVATIVE, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | Shanghai Simr Biotechnology Co., Ltd. (CN) | 2024-06-19 | — | — | EP | disclosed |
| WO-2024116053-A1 | PCTA DERIVATIVES, CONJUGATES THEREOF AND USES THEREOF | NOVARTIS AG (CH) | 2024-06-06 | — | — | WO | disclosed |
| WO-2001025216-A1 | 1-ARYL-1,3-DIHYDRO-IMIDAZOL-2-(THI)ONE DERIVATIVES, PRODUCTION OF SAID COMPOUND AND USE AS A DESSICATING/DEFOLIATING AGENT FOR PLANTS | BASF AKTIENGESELLSCHAFT (DE) | 2001-04-12 | — | — | WO | disclosed |
| EP-1086946-A1 | BENZAMIDINE DERIVATIVE | Ajinomoto Co., Inc. (JP) | 2001-03-28 | — | — | EP | disclosed |
| EP-0835248-B1 | 1-AMINO-3-BENZYLURACILS | BASF AG (DE) | 2001-02-21 | — | — | EP | disclosed |
| WO-2001000602-A1 | SUBSTITUTED UREAS | BASF AKTIENGESELLSCHAFT (DE) | 2001-01-04 | — | — | WO | disclosed |
| WO-2001000600-A1 | N-SUBSTITUTED PERHYDRO DIAZINE | BASF AKTIENGESELLSCHAFT (DE) | 2001-01-04 | — | — | WO | disclosed |
| WO-2000026194-A1 | NOVEL 1-ARYL-4-THIOURACILS | BASF AKTIENGESELLSCHAFT (DE) | 2000-05-11 | — | — | WO | disclosed |
| EP-0835248-A1 | 1-AMINO-3-BENZYLURACILS | BASF AKTIENGESELLSCHAFT (DE) | 1998-04-15 | — | — | EP | disclosed |
| US-5688795-A | URINARY TRACTS OBSTRUCTION | SYNTEX (U.S.A.) INC. (US) | 1997-11-18 | — | — | US | disclosed |
| WO-1997001543-A1 | 1-AMINO-3-BENZYLURACILS | BASF AKTIENGESELLSCHAFT (DE) | 1997-01-16 | — | — | WO | disclosed |
| EP-0711757-A1 | 3-(4-phenylpiperazin-1-yl)propyl-amino, thio and oxy -pyridine, pyrimidine and benzene derivatives as alpha1-adrenoceptor antagonists | F. Hoffmann-La Roche AG (CH) | 1996-05-15 | — | — | EP | disclosed |